-
A.
Tsimberidou,
S.
Wen,
D.
Hong,
J.
Wheler,
G.
Falchook,
S.
Fu,
S.
Piha-Paul,
A.
Naing,
F.
Janku,
K.
Aldape,
Y.
Ye,
R.
Kurzrock,
D.
Berry
(2014)
Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses
Clinical Cancer Research, 20
-
C.
Tourneau,
X.
Paoletti,
N.
Servant,
I.
Bièche,
D.
Gentien,
T.
Frio,
A.
Vincent-Salomon,
V.
Servois,
J.
Roméjon,
O.
Mariani,
V.
Bernard,
P.
Huppé,
G.
Pierron,
F.
Mulot,
C.
Callens,
J.
Wong,
C.
Mauborgne,
E.
Rouleau,
C.
Reyes,
E.
Henry,
Q.
Leroy,
P.
Gestraud,
P.
Rosa,
L.
Escalup,
E.
Mitry,
O.
Trédan,
J.
Delord,
M.
Campone,
A.
Gonçalves,
N.
Isambert,
C.
Gavoille,
M.
Kamal
(2014)
Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial
British Journal of Cancer, 111
-
MaemondoM,
InoueA,
KobayashiK
(2010)
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
N Engl J Med, 362
-
F.
Meric-Bernstam,
Lauren
Brusco,
K.
Shaw,
Chacha
Horombe,
S.
Kopetz,
M.
Davies,
M.
Routbort,
S.
Piha-Paul,
F.
Janku,
N.
Ueno,
D.
Hong,
J.
Groot,
V.
Ravi,
Yisheng
Li,
R.
Luthra,
K.
Patel,
R.
Broaddus,
J.
Mendelsohn,
G.
Mills
(2015)
Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 25
-
HortobagyiGN
(2005)
Trastuzumab in the treatment of breast cancer
N Engl J Med, 353
-
D.
Hoff,
J.
Stephenson,
P.
Rosen,
D.
Loesch,
M.
Borad,
S.
Anthony,
G.
Jameson,
Susan
Brown,
Nina
Cantafio,
D.
Richards,
T.
Fitch,
E.
Wasserman,
C.
Fernandez,
S.
Green,
W.
Sutherland,
M.
Bittner,
A.
Alarcon,
D.
Mallery,
R.
Penny
(2010)
Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 33
-
D.
Hyman,
B.
Taylor,
J.
Baselga
(2017)
Implementing Genome-Driven Oncology
Cell, 168
-
J.
Rodón,
C.
Saura,
R.
Dienstmann,
A.
Vivancos,
S.
Cajal,
J.
Baselga,
J.
Tabernero
(2012)
Molecular prescreening to select patient population in early clinical trials
Nature Reviews Clinical Oncology, 9
-
C.
Tourneau,
M.
Kamal,
A.
Tsimberidou,
Philippe
Bédard,
G.
Pierron,
C.
Callens,
E.
Rouleau,
A.
Vincent-Salomon,
N.
Servant,
M.
Alt,
R.
Rouzier,
X.
Paoletti,
O.
Delattre,
I.
Bièche
(2015)
Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials
JNCI Journal of the National Cancer Institute, 108
-
C.
Tourneau,
J.
Delord,
A.
Gonçalves,
C.
Gavoille,
C.
Dubot,
N.
Isambert,
M.
Campone,
O.
Trédan,
M.
Massiani,
C.
Mauborgne,
Sébastien
Armanet,
N.
Servant,
I.
Bièche,
V.
Bernard,
D.
Gentien,
P.
Jézéquel,
V.
Attignon,
S.
Boyault,
A.
Vincent-Salomon,
V.
Servois,
M.
Sablin,
M.
Kamal,
X.
Paoletti
(2015)
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
The Lancet. Oncology, 16 13
-
F.
Mertens,
B.
Johansson,
T.
Fioretos,
F.
Mitelman
(2015)
The emerging complexity of gene fusions in cancer
Nature Reviews Cancer, 15
-
S.
Maximiano,
Paulo
Magalhães,
M.
Guerreiro,
M.
Morgado
(2016)
Trastuzumab in the Treatment of Breast Cancer
BioDrugs, 30
-
B.
Tran,
J.
Dancey,
S.
Kamel‐Reid,
J.
McPherson,
Philippe
Bédard,
Andrew
Brown,
Tong
Zhang,
P.
Shaw,
N.
Onetto,
Lincoln
Stein,
T.
Hudson,
B.
Neel,
L.
Siu
(2012)
Cancer genomics: technology, discovery, and translation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 6
-
A.
Shaw,
Dong-Wan
Kim,
K.
Nakagawa,
T.
Seto,
L.
Crinò,
M.
Ahn,
T.
Pas,
B.
Besse,
B.
Solomon,
F.
Blackhall,
Yi-long
Wu,
Michael
Thomas,
K.
O'Byrne,
D.
Moro-Sibilot,
D.
Camidge,
T.
Mok,
V.
Hirsh,
Gregory
Riely,
S.
Iyer,
V.
Tassell,
A.
Polli,
K.
Wilner,
P.
Jänne
(2013)
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
The New England journal of medicine, 368 25
-
L.
Alexandrov,
S.
Nik-Zainal,
D.
Wedge,
S.
Aparicio,
S.
Behjati,
A.
Biankin,
G.
Bignell,
N.
Bolli,
Å.
Borg,
A.
Børresen-Dale,
S.
Boyault,
B.
Burkhardt,
A.
Butler,
C.
Caldas,
H.
Davies,
C.
Desmedt,
R.
Eils,
J.
Eyfjörd,
J.
Foekens,
M.
Greaves,
F.
Hosoda,
B.
Hutter,
Tomislav
Ilicic,
S.
Imbeaud,
Marcin
Imielinsk,
N.
Jäger,
David
Jones,
David
Jones,
S.
Knappskog,
M.
Kool,
S.
Lakhani,
C.
López-Otín,
Sancha
Martin,
N.
Munshi,
Hiromi
Nakamura,
P.
Northcott,
M.
Pajic,
E.
Papaemmanuil,
A.
Paradiso,
J.
Pearson,
X.
Puente,
K.
Raine,
Manasa
Ramakrishna,
A.
Richardson,
J.
Richter,
P.
Rosenstiel,
M.
Schlesner,
T.
Schumacher,
P.
Span,
J.
Teague,
Y.
Totoki,
A.
Tutt,
R.
Valdés-Mas,
Marit
Buuren,
L.
Veer,
A.
Vincent-Salomon,
N.
Waddell,
L.
Yates,
J.
Zucman‐Rossi,
P.
Futreal,
U.
McDermott,
P.
Lichter,
M.
Meyerson,
S.
Grimmond,
R.
Siebert,
E.
Campo,
T.
Shibata,
S.
Pfister,
P.
Campbell,
M.
Stratton
(2013)
Signatures of mutational processes in human cancer
Nature, 500
-
T.
Stockley,
A.
Oza,
H.
Berman,
N.
Leighl,
J.
Knox,
F.
Shepherd,
E.
Chen,
M.
Krzyzanowska,
N.
Dhani,
A.
Joshua,
M.
Tsao,
S.
Serra,
B.
Clarke,
M.
Roehrl,
Tong
Zhang,
M.
Sukhai,
N.
Califaretti,
M.
Trinkaus,
P.
Shaw,
T.
Kwast,
Lisa
Wang,
C.
Virtanen,
R.
Kim,
A.
Razak,
A.
Hansen,
Celeste
Yu,
Trevor
Pugh,
S.
Kamel‐Reid,
L.
Siu,
P.
Bedard
(2016)
Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial
Genome Medicine, 8
-
Julie
Reeser,
D.
Martin,
Jharna
Miya,
Esko
Kautto,
E.
Lyon,
Eliot
Zhu,
M.
Wing,
Amy
Smith,
Matthew
Reeder,
Eric
Samorodnitsky,
Hannah
Parks,
Karan
Naik,
J.
Gozgit,
Nicholas
Nowacki,
K.
Davies,
M.
Varella-Garcia,
Lianbo
Yu,
A.
Freud,
J.
Coleman,
D.
Aisner,
S.
Roychowdhury
(2017)
Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors.
The Journal of molecular diagnostics : JMD, 19 5
-
T.
Pincez,
N.
Clément,
E.
Lapouble,
G.
Pierron,
M.
Kamal,
I.
Bièche,
V.
Bernard,
P.
Fréneaux,
J.
Michon,
D.
Orbach,
I.
Aerts,
H.
Pacquement,
F.
Bourdeaut,
I.
Jimenez,
E.
Thébaud,
C.
Oudot,
C.
Vérité,
S.
Taque,
C.
Owens,
F.
Doz,
C.
Tourneau,
O.
Delattre,
G.
Schleiermacher
(2017)
Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumors
Pediatric Blood & Cancer, 64
-
S.
Gray,
K.
Hicks-Courant,
A.
Cronin,
B.
Rollins,
J.
Weeks
(2014)
Physicians' attitudes about multiplex tumor genomic testing.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 13
-
S.
Postel-Vinay,
Y.
Boursin,
C.
Massard,
A.
Hollebecque,
E.
Ileana,
M.
Chiron,
J.
Jung,
J.
Lee,
Z.
Balogh,
J.
Adam,
P.
Vielh,
E.
Angevin,
L.
Lacroix,
J.
Soria
(2016)
Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?
Annals of oncology : official journal of the European Society for Medical Oncology, 27 2
-
P.
Chapman,
A.
Hauschild,
C.
Robert,
J.
Haanen,
P.
Ascierto,
J.
Larkin,
R.
Dummer,
C.
Garbe,
A.
Testori,
M.
Maio,
D.
Hogg,
P.
Lorigan,
C.
Lebbé,
T.
Jouary,
D.
Schadendorf,
A.
Ribas,
S.
O'Day,
J.
Sosman,
J.
Kirkwood,
A.
Eggermont,
B.
Dréno,
K.
Nolop,
Jiang
Li,
B.
Nelson,
J.
Hou,
Richard
Lee,
K.
Flaherty,
G.
McArthur
(2011)
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
The New England journal of medicine, 364 26
-
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)
-
C.
Massard,
S.
Michiels,
C.
Ferté,
M.
Deley,
L.
Lacroix,
A.
Hollebecque,
L.
Verlingue,
E.
Ileana,
S.
Rosellini,
S.
Ammari,
M.
Ngo-Camus,
R.
Bahleda,
A.
Gazzah,
A.
Varga,
S.
Postel-Vinay,
Y.
Loriot,
C.
Even,
I.
Breuskin,
N.
Auger,
B.
Job,
T.
Baère,
F.
Deschamps,
P.
Vielh,
J.
Scoazec,
V.
Lazar,
C.
Richon,
V.
Ribrag,
E.
Deutsch,
E.
Angevin,
G.
Vassal,
A.
Eggermont,
F.
André,
J.
Soria
(2017)
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.
Cancer discovery, 7 6
-
M.
Harris,
S.
DuBois,
J.
Bender,
AeRang
Kim,
B.
Crompton,
Erin
Parker,
Ian
Dumont,
A.
Hong,
Dongjing
Guo,
A.
Church,
K.
Stegmaier,
C.
Roberts,
S.
Shusterman,
W.
London,
L.
Macconaill,
N.
Lindeman,
L.
Diller,
C.
Rodríguez-Galindo,
K.
Janeway
(2016)
Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study.
JAMA oncology, 2 5
-
M.
Maemondo,
Inoue
(2010)
F1000 highlights
Asia‐Pacific Journal of Clinical Oncology, 6
-
E.
Aguirre,
K.
Amillano,
A.
Cortés,
M.
Juan,
A.
Márquez,
M.
Ruiz,
S.
Servitja,
A.
Urrutikoetxea,
A.
Llombart,
J.
Pérez,
J.
Cortés
(2018)
Abstract CT165: A two-stage Simon Design phase II study for NOn-BRCA metastatic BReast cancer (MBC)patients with homologous recombination deficiency treated with OLAparib single agent.(NOBROLA study)
Clinical Trials
-
A Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With Olaparib Single Agent (NOBROLA)
-
Lisa
Belin,
M.
Kamal,
C.
Mauborgne,
C.
Plancher,
F.
Mulot,
J.
Delord,
A.
Gonçalves,
C.
Gavoille,
C.
Dubot,
Nicolas
Isambert,
M.
Campone,
O.
Trédan,
Francesco
Ricci,
M.
Alt,
D.
Loirat,
M.
Sablin,
X.
Paoletti,
V.
Servois,
C.
Tourneau,
C.
Tourneau
(2016)
Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial
Annals of Oncology, 28
-
D.
Hanahan,
R.
Weinberg
(2011)
Hallmarks of Cancer: The Next Generation
Cell, 144
-
F.
André,
T.
Bachelot,
F.
Commo,
M.
Campone,
M.
Arnedos,
V.
Diéras,
M.
Lacroix-Triki,
L.
Lacroix,
P.
Cohen,
D.
Gentien,
J.
Adélaide,
F.
Dalenc,
A.
Gonçalves,
C.
Lévy,
J.
Ferrero,
J.
Bonneterre,
C.
Lefeuvre,
M.
Jimenez,
T.
Filleron,
H.
Bonnefoi
(2014)
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER).
The Lancet. Oncology, 15 3